都說創(chuàng)業(yè)很難，在創(chuàng)業(yè)期間遇到的問題都是前所未有的，在大多數(shù)創(chuàng)業(yè)者所遇到的問題中，股權(quán)分配是讓大家最頭疼的問題。

為此，我們特意邀請(qǐng)了康橋資本(CBC Group)投資副總裁陳家岐博士（Stephen Chan）以“創(chuàng)業(yè)公司如何進(jìn)行股權(quán)設(shè)計(jì)”為主題為初期創(chuàng)業(yè)者分享相關(guān)的內(nèi)容，以期能夠幫助生物醫(yī)療領(lǐng)域創(chuàng)業(yè)者解決創(chuàng)業(yè)初期的實(shí)際性問題。

活動(dòng)主題

創(chuàng)業(yè)公司如何進(jìn)行股權(quán)設(shè)計(jì)？

??Different types of shares in a company, how do they differ from each other?

??What is the right share equity for founders?

??How to incentives the team with shares equity?

??How to deal with leavers with ESOP?

??Key considerations when engaging with VC for financing, what are the potential pitfalls and things to watch out?

時(shí)間及地點(diǎn)

日期及時(shí)間：

2021-05-29 10:30AM BJT

2021-05-28 7:30PM PDT

2021-05-28 10:30PM EDT

地點(diǎn)：zoom線上會(huì)議室

語言：英文

主講人

陳家岐博士（Stephen Chan）

康橋資本投資副總裁

陳家岐博士（Stephen Chan）目前是康橋資本(CBC Group)醫(yī)藥行業(yè)的投資副總裁?？禈蛸Y本是一家以醫(yī)療保健為重點(diǎn)的私募股權(quán)基金，管理著超過35億美元的資產(chǎn)。在康橋資本，陳家岐博士主要專注于跨新興技術(shù)前沿的新公司孵化，特別關(guān)注基因和細(xì)胞治療領(lǐng)域。

在加入康橋資本之前，陳家岐博士曾領(lǐng)導(dǎo)和高資產(chǎn)管理有限公司（Co-High Investment）的醫(yī)療健康投資團(tuán)隊(duì)，和高資產(chǎn)管理有限公司總部位于香港，由西澤投資管理公司（Atlantis Investment）所投資。在和高資產(chǎn)管理有限公司，陳家岐博士管理著1億美元規(guī)模的醫(yī)療基金，他曾投資的公司包括：Oxford Nanopore、Sera Pronotics、Promethera Biosciences。

在加入和高資產(chǎn)管理有限公司之前，陳家岐博士是麥肯錫公司(Mckinsey & Company)的高級(jí)戰(zhàn)略顧問，為全球制藥公司提供研發(fā)和戰(zhàn)略投資咨詢服務(wù)。陳家岐博士本科畢業(yè)于倫敦帝國(guó)學(xué)院生物化學(xué)專業(yè)，博士就讀于劍橋大學(xué)，并獲得遺傳學(xué)博士學(xué)位，曾獲取裘槎獎(jiǎng)學(xué)金（Croucher Scholarships）。

英文介紹：

Stephen currently serves as Investment Vice President (Pharma) at CBC Group, a leading healthcare focused private equity firm with over US$3.5Bn AUM. At CBC, Stephen mainly focused on new company incubation across multiple emerging technology fronts with a particular focus on gene and cell therapy. Prior to CBC Group, Stephen heads the Healthcare Investment team of Co-High Investment, a private equity and venture investment arm of Hong Kong based Atlantis Investment. At Co-High, Stephen manages a dedicated US$100Mn healthcare fund, his selected prior investment includes, Oxford Nanopore Technologies, Sera Prognostics, Promethera Biosciences. Before Co-High, Stephen was a senior Strategy Consultant at Mckinsey & Co. where he advised global pharmacos on R&D and investment strategy. Stephen graduated with a Ph.D. in genetics from The University of Cambridge, where he was also a Croucher Scholar; he also obtained a 1st class B.Sc. in Biochemistry from Imperial College London.

關(guān)于康橋資本(CBC Group)：

康橋資本(CBC Group)是亞洲最大和最活躍的醫(yī)療健康行業(yè)的私募股權(quán)基金之一，專注于生物醫(yī)藥、醫(yī)療器械和醫(yī)療服務(wù)三個(gè)核心領(lǐng)域的平臺(tái)建設(shè)和收購(gòu)機(jī)遇?？禈蛸Y本賦能醫(yī)療健康行業(yè)領(lǐng)軍企業(yè)的變革，以實(shí)現(xiàn)長(zhǎng)期可持續(xù)增長(zhǎng)，解決尚未滿足的醫(yī)療需求，不斷提高中國(guó)和亞洲其他地區(qū)的全民醫(yī)療健康水平及生活質(zhì)量。康橋資本成立于2014年，在新加坡、上海、北京、香港和紐約擁有強(qiáng)大的投資、醫(yī)療和投資組合管理的專業(yè)團(tuán)隊(duì)。

About CBC Group

CBC Group (formerly C-Bridge Capital) is one of the largest and most active healthcare-dedicated investment firms in Asia focused on platform-building and buyout opportunities across three core areas within the healthcare sector: pharmaceutical & biotech, medtech and healthcare services. CBC’s operationally intensive approach empowers healthcare sector champions to make transformative changes to enable sustainable long-term growth, fulfill unmet medical needs and continuously improve the standard of living and quality of care in China and the rest of Asia. Founded in 2014, CBC has a strong team of investment, healthcare and portfolio management professionals based across Singapore, Shanghai, Beijing, Hong Kong and New York.

活動(dòng)流程

10:30~10:35?主持人開場(chǎng)?

10:35~11:05?嘉賓主題演講?

11:05~11:25?Q&A環(huán)節(jié)?

11:25~11:30?主持人結(jié)束詞?

聯(lián)合主辦方